Inari Medical, Inc.
NARIUnited States
18 filed reports · 345 financial concepts
Latest figures
Group totals as stated in the company’s own filed reports, each with a link to its report. The change is against the same period a year earlier.
| Figure | Latest fiscal year | Latest quarter |
|---|---|---|
| Revenue | $494MFY2023 · to Dec 31, 2023+28.7% from $383M10-K | $153MQ3 FY2024 · to Sep 30, 2024+21.4% from $126M10-Q |
| Net income | -$1.64MFY2023 · to Dec 31, 2023a year earlier: -$29.3M10-K | -$18.4MQ3 FY2024 · to Sep 30, 2024a year earlier: $3.16M10-Q |
| Operating income | -$14MFY2023 · to Dec 31, 2023a year earlier: -$28.1M10-K | -$13.6MQ3 FY2024 · to Sep 30, 2024a year earlier: $2.11M10-Q |
Filed reports
18 reports · Jun 2020 to Sep 2024Each report counts once it has at least one extracted financial fact.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 14 | 2,326 | Jun 2020 to Sep 2024 |
| Annual · 10-KSEC EDGAR | 4 | 1,769 | Dec 2020 to Dec 2023 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2024 Q3 | 10-Q | Sep 30, 2024 | Oct 28, 2024 | 381 | Open |
| FY2024 Q2 | 10-Q | Jun 30, 2024 | Jul 30, 2024 | 218 | Open |
| FY2024 Q1 | 10-Q | Mar 31, 2024 | Apr 30, 2024 | 224 | Open |
| FY2023 | 10-K | Dec 31, 2023 | Feb 29, 2024 | 746 | Open |
| FY2023 Q3 | 10-Q | Sep 30, 2023 | Nov 1, 2023 | 160 | Open |
| FY2023 Q2 | 10-Q | Jun 30, 2023 | Aug 2, 2023 | 129 | Open |
| FY2023 Q1 | 10-Q | Mar 31, 2023 | May 3, 2023 | 131 | Open |
| FY2022 | 10-K | Dec 31, 2022 | Feb 27, 2023 | 414 | Open |
| FY2022 Q3 | 10-Q | Sep 30, 2022 | Nov 2, 2022 | 151 | Open |
| FY2022 Q2 | 10-Q | Jun 30, 2022 | Aug 3, 2022 | 143 | Open |
| FY2022 Q1 | 10-Q | Mar 31, 2022 | May 4, 2022 | 131 | Open |
| FY2021 | 10-K | Dec 31, 2021 | Feb 23, 2022 | 359 | Open |
Financial data
345 concepts · 4,095 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial338 concepts · 4,005 facts · Dec 2018 to Sep 2024
- Stockholders equity (US GAAP)30 · Dec 2018 to Sep 2024
- Adjustments to additional paid in capital sharebased compensation requisite service period recognition value29 · Dec 2018 to Sep 2024
- Allocated share based compensation expense29 · Dec 2018 to Sep 2024
- Cash cash equivalents restricted cash and restricted cash equivalents29 · Dec 2018 to Sep 2024
- Cost of goods and services sold (US GAAP)29 · Dec 2018 to Sep 2024
- Gross profit (US GAAP)29 · Dec 2018 to Sep 2024
- Income loss from continuing operations before income taxes extraordinary items noncontrolling interest29 · Dec 2018 to Sep 2024
- Income tax expense benefit29 · Dec 2018 to Sep 2024
- Investment income interest29 · Dec 2018 to Sep 2024
- Net income loss29 · Dec 2018 to Sep 2024
- Operating expenses (US GAAP)29 · Dec 2018 to Sep 2024
- Operating income loss29 · Dec 2018 to Sep 2024
- Other nonoperating income expense29 · Dec 2018 to Sep 2024
- Research and development expense29 · Dec 2018 to Sep 2024
- Selling general and administrative expense29 · Dec 2018 to Sep 2024
- Stock issued during period value stock options exercised29 · Dec 2018 to Sep 2024
- Amortization of financing costs27 · Dec 2018 to Sep 2024
- Antidilutive securities excluded from computation of earnings per share amount27 · Dec 2018 to Sep 2024
- Cash cash equivalents restricted cash and restricted cash equivalents period increase decrease including exchange rate effect27 · Dec 2018 to Sep 2024
- Income taxes paid net27 · Dec 2018 to Sep 2024
- Increase decrease in accounts payable27 · Dec 2018 to Sep 2024
- Increase decrease in accounts receivable27 · Dec 2018 to Sep 2024
- Increase decrease in inventories27 · Dec 2018 to Sep 2024
- Interest expense (US GAAP)27 · Dec 2018 to Mar 2024
Product2 concepts · 56 facts · Dec 2018 to Sep 2024
- Percentage Of Revenue36 · Dec 2018 to Dec 2022
- Revenue20 · Dec 2021 to Sep 2024
Geography5 concepts · 34 facts · Dec 2020 to Sep 2024
- Revenue28 · Dec 2020 to Sep 2024
- Increase in Operating Lease Right Of Use Asset2 · Dec 2022
- Number Of Additional Warehouse Spaces2 · Mar 2021 to Dec 2021
- Operating lease lease income lease payments1 · Dec 2021
- Operating Leases Number Of Lease Period Extension Options1 · Mar 2021
Segments
90 factsFigures broken down by business line, region, product or another axis the company reports on.
Product or service6 members · 56 facts
- ClotTriever Products15 · Dec 2018 to Sep 2022
- FlowTriever Products15 · Dec 2018 to Sep 2022
- Emerging Therapies10 · Dec 2021 to Sep 2024
- VTE10 · Dec 2021 to Sep 2024
- ClotTriever and other systems3 · Dec 2020 to Dec 2022
- FlowTriever system3 · Dec 2020 to Dec 2022
Statement geographical5 members · 34 facts
- Non-US14 · Dec 2020 to Sep 2024
- United States14 · Dec 2020 to Sep 2024
- Irvine, California3 · Mar 2021 to Dec 2022
- Lake Forest, California and Irvine, California2 · Mar 2021 to Dec 2021
- Switzerland1 · Dec 2022
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
Transcripts with management claims and analyst questions, one per fiscal period.
No earnings-call transcripts for this company.
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Ask about this company in your AI model
Connect FactIQ to Claude, ChatGPT or another AI model (how to install), then paste this prompt.
Use FactIQ to get the revenue, net income and operating income of Inari Medical, Inc. (NARI) from its filed reports, for the last five fiscal years and the latest quarter or half year. Link each figure to its filing, and chart the trend.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Nov 16, 2026) and refreshed every few hours.